Hundreds of Virus Patients Allowed to Try Gilead’s Ebola Drug
Hundreds of coronavirus patients have been treated with Gilead’s experimental Ebola treatment under an FDA program to allow access to
Tag: FDA
Axsome Therapeutics Announces Acceleration of MOMENTUM Phase 3 Trial of AXS-07 in Migraine
Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today
Sage Therapeutics Announces FDA Approval of ZULRESSO™ (SBECD-enabled brexanolone) Injection, the First and Only Treatment Specifically Indicated for Postpartum Depression
Approval based on results from three pivotal trials showing treatment with ZULRESSO provided significant and rapid reduction of depressive symptoms
Sage Therapeutics Announces FDA Advisory Committee Votes 17-1 in Support of Benefit-Risk Profile of ZULRESSO™ (brexanolone) Injection for Treatment of Postpartum Depression
If approved, ZULRESSO would be the first medicine specifically indicated for the treatment of postpartum depression (PPD) Sage Therapeutics (NASDAQ:
FDA Approves KYPROLIS® (carfilzomib) In Combination With Dexamethasone For Patients With Relapsed Or Refractory Multiple Myeloma
Amgen (NASDAQ:AMGN) recently announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA)
Amgen Submits Supplemental New Drug Application For KYPROLIS® (carfilzomib)
Amgen announced on the 27th August, 2018 the submission of a supplemental New Drug Application (sNDA) to the U.S. Food
Video-class on Pharmacokinetics, Toxicology and Regulatory Status of Cyclodextrins
The video of Prof. Thorsteinn Loftsson on the website of CycloHit project gives a summary on the physicochemical and pharmacokinetic
First cannabidiol product approved by FDA as medication
Cannabis has been used for medicinal purposes for thousands of years. Its active compounds produce pharmacological effects throughout the body,